internal
Robert A. Michael
Chairman of the Board and Chief Executive Officer
Executive
2 yr
22 reports
Leadership change Robert A. Michael was promoted to Chairman and CEO (from CEO) · DEF 14A 2026-03-23
AbbVie Inc. ·ABBV
Single global segment with unusually broad CEO functional span
Pharmaceuticals · Fortune #67 · Functional structure · 50K employees · North Chicago, IL
View as of:
8
CEO span
↓ tighter than peers (avg 10)
3.1
Avg span
moderate
3
Max depth
3 levels
4.9 yr
Avg tenure
stable vs FY2024
86%
Internal hires
↑ above industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$61.2B
Operating income
$15.1B
Net income
$4.2B
Total assets
$134.0B
Shares out
1.77B
Sourced from AbbVie Inc. DEF 14A · filed 2026-03-23 ↗ View on SEC
Interactive org chart
AbbVie Inc. organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
Single global segment with unusually broad CEO functional span. This page maps AbbVie’s functional leadership structure, detailing the executive team, reporting lines, key departments, recent leadership changes, historical snapshots, and peer comparisons.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Robert A. Michael moved into Chairman and CEO
Promoted to Chairman effective July 1, 2025.
Source · See change logScenario views in the chart
- Add Chief AI Officer Introduce a Chief AI Officer to coordinate data, AI and digital strategy across R&D and commercial functions.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
8 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
internal
Roopal B. Thakkar
Executive Vice President, Research & Development and Chief Scientific Officer
R&D
4 yr
3 reports
internal
Jeffrey R. Stewart
Executive Vice President and Chief Commercial Officer
Commercial
6 yr
4 reports
internal
Azita Saleki-Gerhardt
Executive Vice President and Chief Operations Officer
Operations
5 yr
3 reports
internal
Scott T. Reents
Executive Vice President and Chief Financial Officer
Finance
7 yr
3 reports
internal
Perry C. Siatis
Executive Vice President, General Counsel and Secretary
Legal
3 yr
2 reports
Open Role
Senior Vice President, Corporate Affairs
Corporate Affairs
1 yr
0 reports
Open Role
Senior Vice President, Corporate Strategy
Strategy
1 yr
0 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 5 named executive officers disclosed. Bar length scales with total compensation.
Robert A. Michael $32.5M
- Base salary
- $1.70M
- Stock awards
- $13.27M
- Option awards
- $3.20M
- Non-equity incentive
- $5.20M
- Pension change
- $8.65M
- Other
- $516K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Scott T. Reents $12.4M
- Base salary
- $1.12M
- Stock awards
- $4.35M
- Option awards
- $1.05M
- Non-equity incentive
- $2.35M
- Pension change
- $3.00M
- Other
- $473K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Jeffrey R. Stewart $15.4M
- Base salary
- $1.32M
- Stock awards
- $5.39M
- Option awards
- $1.30M
- Non-equity incentive
- $2.95M
- Pension change
- $3.74M
- Other
- $737K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Azita Saleki-Gerhardt $10.8M
- Base salary
- $1.05M
- Stock awards
- $3.98M
- Option awards
- $960K
- Non-equity incentive
- $2.20M
- Pension change
- $1.78M
- Other
- $820K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Roopal B. Thakkar $9.9M
- Base salary
- $1.15M
- Stock awards
- $3.98M
- Option awards
- $960K
- Non-equity incentive
- $2.35M
- Pension change
- $1.42M
- Other
- $60K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The skin in the game
Beneficial ownership
Insider stock holdings and the company's ownership requirements for executives and directors. Disclosed in the most recent DEF 14A.
Stock ownership requirements
6×CEO base salary
3×NEO base salary
5×Director cash retainer
Minimum stock ownership guidelines disclosed in proxy.
The businesses
How AbbVie Inc. divides the work
5 divisions report into the group CEO. Tile size scales with estimated headcount.
Research & Development
15K employees
EVP R&D & Chief Scientific Officer (Roopal B. Thakkar)
Global discovery and development across immunology, oncology, neuroscience and aesthetics.
Commercial
14K employees
EVP & Chief Commercial Officer (Jeffrey R. Stewart)
Global marketing, sales, market access and customer engagement.
Operations
12K employees
EVP & Chief Operations Officer (Azita Saleki-Gerhardt)
Manufacturing, supply chain, quality and operational excellence.
Finance
3K employees
EVP & Chief Financial Officer (Scott T. Reents)
Financial planning, reporting, treasury and tax.
Legal & Compliance
2K employees
EVP, General Counsel (Perry C. Siatis)
Legal, IP, compliance and governance.
The thesis
Why this org is unusual
Single global segment governance means the CEO retains direct oversight of nearly all core functions, resulting in a wider-than-peer functional span.
AbbVie’s org shows eight direct CEO reports covering finance, commercial, operations, R&D, legal, strategy and corporate affairs, with no divisional presidents or P&L owners. This reinforces centralized capital allocation and portfolio control.
The structure aligns with AbbVie’s single operating segment disclosure in its 10-K, where the CEO acts as chief operating decision maker across R&D, manufacturing, and commercialization. Functional depth appears at level three, where therapeutic-area R&D and commercial execution sit under centralized leaders rather than semi-autonomous divisions.
- Single operating segment
- No divisional presidents
- Wide CEO functional span
The comparison
How AbbVie Inc. stacks up
Compared with large pharma peers, AbbVie’s structure is more centralized. Companies like Pfizer and J&J operate with clearer business-unit or platform heads with P&L authority, increasing depth but reducing CEO span. AbbVie instead concentrates authority at the top. This model resembles Merck more than Bristol …
C-suite size
Reporting depth
AbbVie Inc.
3 levels
5 levels
4 levels
5 levels
6 levels
4 levels
Avg C-suite tenure
Has COO / Has CAIO
AbbVie Inc. — no COO — no CAIO
Current signals
What changed recently
The most consequential change was Robert Michael assuming the Chairman role in July 2025, consolidating leadership.
- promoted
- departed
- new
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-03-23
- CEO
- Robert A. Michael
- CEO span
- 8
- C-suite
- 5
- Avg tenure
- 4.9 yr
CEO also serves as Chairman, with centralized functional oversight.
Named executive officers (5)
- Robert A. Michael - CEO since 2024
- Scott T. Reents - CFO since 2018
- Jeffrey R. Stewart - CCO since 2019
- Azita Saleki-Gerhardt - COO since 2020
- Roopal B. Thakkar - CSO since 2021
FY2024
DEF 14A filed 2025-03-24
- CEO
- Robert A. Michael
- CEO span
- 7
- C-suite
- 6
- Avg tenure
- 5.1 yr
Transition year with outgoing Executive Chairman.
Named executive officers (6)
- Robert A. Michael - CEO since 2024
- Richard A. Gonzalez - Executive Chairman since 2013
- Scott T. Reents - CFO since 2018
- Jeffrey R. Stewart - CCO since 2019
- Azita Saleki-Gerhardt - COO since 2020
- Timothy J. Richmond - CHRO since 2020
FY2023
DEF 14A filed 2024-03-22
- CEO
- Richard A. Gonzalez
- CEO span
- 6
- C-suite
- 6
- Avg tenure
- 6.3 yr
Founder-era leadership nearing transition.
Named executive officers (5)
- Richard A. Gonzalez - CEO since 2013
- Robert A. Michael - CFO since 2018
- Scott T. Reents - CFO since 2018
- Jeffrey R. Stewart - CCO since 2019
- Azita Saleki-Gerhardt - COO since 2020
Year-over-year changes
Leadership consolidated as Michael assumed the Chair role and Gonzalez exited.
- CEO span: 7 → 8
- C-suite size: 6 → 5
- Avg tenure: 5.1 → 4.9 yr
- promoted Robert A. Michael - Chairman and CEO (was CEO) (DEF 14A 2026-03-23)
- departed Richard A. Gonzalez - Executive Chairman (was Executive Chairman) (DEF 14A 2026-03-23)
Frequently Asked Questions
Who is the CEO of AbbVie?
Robert A. Michael has served as AbbVie’s CEO since July 2024 and became Chairman in July 2025.
What type of organizational structure does AbbVie use?
AbbVie uses a functional structure with a single global operating segment.
How many direct reports does AbbVie’s CEO have?
The CEO has eight direct reports covering all major functions.
How has AbbVie’s leadership changed recently?
Recent changes include Robert Michael becoming Chairman and the retirement of Richard Gonzalez in mid‑2025.
Who reports directly to AbbVie’s CEO?
Finance, Commercial, Operations, R&D, Legal, Strategy and Corporate Affairs leaders all report directly to the CEO.
Sources
- Form 8-K, May 2025
- SEC EDGAR: AbbVie Inc. DEF 14A Proxy Statement
- SEC EDGAR: AbbVie Inc. 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). AbbVie Inc. organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/abbvie/MLA 9th
"AbbVie Inc. Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/abbvie/. Accessed .Chicago 17
Creately. "AbbVie Inc. Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/abbvie/.Original SEC source View on SEC ↗
AbbVie Inc.. DEF 14A. Filed 2026-03-23. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htmPermanent URL: https://creately.com/org-chart/fortune-500/abbvie/ · last updated 2026-04-01